Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.4  

 
 

MASTER SERVICES AGREEMENT    
    

        THIS MASTER SERVICES AGREEMENT (this "Agreement") is entered into
this 6th day of April, 2004 (the "Effective Date") by and between CELLDEX
THERAPEUTICS, INC., a Delaware corporation, with principal offices located at 519 Route 173 W, Bloomsbury, NJ 08804
("Celldex"), and MEDAREX, INC., a New Jersey corporation, with principal offices located at 707
State Road, Princeton, NJ 08540 ("Medarex"). 

WITNESSETH:  

        WHEREAS, Medarex has determined that it would be in the best interests of Medarex and its shareholders to separate certain assets and businesses from Medarex; 

        WHEREAS,
Medarex has caused Celldex to be incorporated in order to effectuate such separation; 

        WHEREAS,
Medarex has heretofore, directly or indirectly, provided certain support services to Celldex; 

        WHEREAS,
on the terms and conditions set forth herein, Celldex may desire to engage Medarex as an independent contractor on a transitional basis to provide, directly or indirectly,
certain services set forth in detail on Exhibit A hereto (the "Services") to Celldex after the
Effective Date; and 

        WHEREAS,
on the terms and conditions set forth herein, Medarex desires to provide those Services to Celldex that Celldex requests and that Medarex agrees to provide; 

        NOW
THEREFORE, in consideration of the premises and of the following mutual promises, covenants and conditions herein contained, and intending to be legally bound, Medarex and Celldex
agree as follows: 

1.     PURCHASE AND SALE OF SERVICES

        1.1    Purchase and Sale of Services.    On the terms and conditions set forth in this Agreement and in consideration
of the Service Charges (as defined in Section 2.1), Medarex agrees to provide to Celldex, and Celldex agrees to purchase from Medarex, those Services that the parties mutually agree upon in
accordance with this Section 1.1: 

        (a)   Celldex
may, in its sole discretion, request in writing on a calendar quarter-by-calendar quarter basis that Medarex provide any of the Services
described in Exhibit A. Any such request shall be made at least ninety (90) days, or such other time period that the parties mutually
agree upon, prior to the first day of the calendar quarter during which Celldex wishes Medarex to provide the designated Services. Medarex shall be under no obligation to provide the Services
requested by Celldex unless expressly and mutually agreed by the parties and set forth on a Service Provision Form (as defined below). 

        (b)   The
parties shall negotiate in good faith the scope and nature of any Services to be provided, including the timeframes and costs for provision, any Deliverables (as
defined below) to be provided, any key Medarex personnel to be involved, and any other relevant details. Each of the Services and all such details mutually agreed upon by the parties shall be set
forth in substantially the form attached hereto as Exhibit B (the "Service Provision Form"). Each
Service Provision Form shall describe a specific single Service that Medarex will provide and shall be signed by a Senior Vice President of Medarex and an officer of Celldex and attached hereto as  Exhibit C, with each subsequent Service Provision Form being appended hereto as a sequentially 

1

 

labeled
exhibit. For example, the first Service shall be labeled as Exhibit C-1, the second Service shall be labeled as  Exhibit C-2, etc. Any amendments
to or extensions of an executed Service Provision Form shall be signed by a Senior Vice President of
Medarex and an officer of Celldex and appropriately entitled and appended to the relevant sequentially numbered exhibit. 

        (c)   The
parties agree that, unless otherwise specified in an executed Service Provision Form, each Service shall be provided on a calendar quarterly basis, subject to
renewal upon a calendar quarterly basis if the parties mutually agree with respect thereto within thirty (30) days prior to the end of the then-current calendar quarter. In
addition, either party may, within thirty (30) days prior to the end of the then current calendar quarter, request terminations or revisions to the provision of any Service, in which case the
parties will in good faith discuss such requested terminations or revisions. Any such termination or revision request shall be made in writing, signed by a Senior Vice President of Medarex and an
officer of Celldex, and appended to the relevant Service Provision Form in accordance with Section 1.1(b). 

        1.2    Additional Services.    In addition to the Services to be provided by Medarex as set forth on Exhibit A
and agreed to in writing by the parties, if requested by Celldex, and to the extent that Medarex and Celldex may mutually agree in writing, Medarex shall provide additional services to Celldex. The
scope and nature of any such additional services shall be as mutually agreed in writing, executed and appended to this Agreement by the parties in accordance with Section 1.1(b). Nothing herein
shall create any obligation on the part Celldex to request, or of Medarex to provide, any additional services. Any such agreed additional services shall thereafter be deemed
"Services" for purposes of this Agreement. 

        1.3    Services Performed by Third Parties.    At its sole option, Medarex shall have the right to cause any Service
it provides hereunder to be provided by any third party that is in the business of providing such services (an "Outsourced Service");  provided, that
(a) Medarex gives Celldex thirty (30) days' prior written notice of its intention to outsource a Service, including all
material details pertaining to such outsourcing, such as the name of the proposed provider and any cost differences; (b) Celldex shall have the right upon written notice to Medarex given within
twenty (20) days following Celldex's receipt of the notice referred to in (a) above, to terminate, without penalty or delay, such Service proposed to be outsourced, together with the related
Service Provision Form relating to such Service; (c) the costs for an Outsourced Service, if outsourced during the term of any executed Service Provision Form, shall not exceed the costs agreed
in such Service Provision Form; and (d) Medarex shall remain responsible for performance, in accordance with the terms of this Agreement, of any Outsourced Service, including compliance with
any such provider with the provisions of Section 5.1 (Confidentiality). 

        1.4    Service Levels; Personnel.    Medarex shall provide the Services in a professional and businesslike manner, by
qualified personnel, on a timely basis, and in accordance with the applicable executed Service Provision Form. Medarex shall comply at all times with all foreign and United States federal, state and
local laws and regulations applicable to it in connection with its performance of the Services and its other obligations under this Agreement. Unless otherwise specified in an executed Service
Provision Form and subject to this Section 1.4, the selection of the Medarex personnel to perform a Service shall in each case be at the sole and reasonable discretion of Medarex. In the event
the employment with Medarex of any key personnel agreed between Celldex and Medarex to perform any Services, as set forth in an executed Service Provision Form, is terminated, or if Celldex notifies
Medarex that it is dissatisfied with the performance by any personnel of Medarex performing Services, Medarex shall use commercially reasonable efforts to promptly replace, for purposes of performing
the applicable Services, such personnel with personnel of comparable ability, skill, and experience. 

        1.5    Equipment and Supplies.    Except as may be expressly set forth in an executed Service Provision Form, Medarex
will be responsible for providing all office supplies (including, to the extent already owned and/or used by Medarex, software and hardware) that may be necessary for the 

2

 

provision
of Services. In the event that Medarex purchases or otherwise acquires additional equipment, software or hardware, as expressly provided for in a Service Provision Form, for the purpose of
performing the Services, Celldex shall reimburse Medarex for the actual cost of such acquired equipment. Celldex shall thereafter own all right, title and interest in and to such acquired equipment. 

        1.6    Deliverables    An executed Service Provision Form may provide that Medarex deliver to or prepare for Celldex
as part of the Services certain information and/or data ("Deliverables") as detailed therein. Except as provided in Section 1.7 hereof, as
between Celldex and Medarex, Celldex shall own all statutory and common law rights, including copyright and other intellectual property rights, to all Deliverables, whether prepared by Medarex or its
employees, independent contractors or any other third party providers. 

        1.7    Product Developments.    With respect to the Services provided by Medarex that are clinical and regulatory
support services ("Clinical/Regulatory Services"): 

        (a)   Medarex
shall make full and prompt written disclosure to Celldex of all inventions, innovations, improvements, modifications, know-how, discoveries and
developments, whether or not patentable or copyrightable (collectively, "Clinical/Regulatory IP"), that are conceived or reduced to practice by or under
the direction of Medarex, alone or jointly with others, during the course of performing Clinical/Regulatory Services. 

        (b)   Celldex
shall own all right, title and interest in and to any Clinical/Regulatory IP that is directly and solely related to the Celldex product that is the subject of
such Clinical/Regulatory Services ("Celldex Product Developments"). Medarex shall execute assignments of ownership with respect to Celldex Product
Developments and shall be responsible for obtaining assignments of ownership from third parties sufficient to transfer to or vest in Celldex the rights to Celldex Product Developments described in
this Section 1.7(b), at no additional charge to Celldex. 

        (c)   For
the avoidance of doubt, "Celldex Product Developments" shall not include Clinical/Regulatory IP that is conceived or reduced to practice by or under the direction of
Medarex, alone or jointly with others, during the course of performing Clinical/Regulatory Services, where such Clinical/Regulatory IP is not related directly and solely to the Celldex product that is
the subject of such Clinical/Regulatory Services ("Medarex Developments"). Medarex Developments include, without limitation, Medarex's methodologies or
processes of conducting clinical studies and protocol development. As between Medarex and Celldex, subject to Sections 1.7(d) and 1.7(e), Medarex shall retain ownership of all right, title and
interest in and to Medarex Developments. 

        (d)   In
the event that a Medarex Development constitutes a Deliverable, Medarex shall grant, and does hereby grant, to Celldex a worldwide, royalty-free,
nonexclusive, perpetual license, with the right to sublicense, to use such Medarex Development as reasonably necessary for Celldex to fully utilize such Deliverable. Promptly following the first
disclosure, pursuant to Section 1.7(a), of a Medarex Development that constitutes a Deliverable, Medarex and Celldex shall enter into a license agreement containing all of the rights and
responsibilities of the parties with respect to the license granted in the first sentence of this Section 1.7(d). Such license agreement shall be negotiated in good faith by the parties and
shall contain commercially reasonable terms, which terms shall not be inconsistent with the first sentence of this Section 1.7(d). Thereafter, any Medarex Developments that constitute a
Deliverable shall be subject to the terms and conditions of such license agreement. 

        (e)   In
the event that a Medarex Development does not constitute a Deliverable, Medarex hereby agrees that, upon the written request of Celldex, Medarex shall negotiate in
good faith with Celldex the terms and conditions of an agreement between Celldex and Medarex pursuant to which Medarex shall grant to Celldex a worldwide, royalty-free, nonexclusive
license, with the right to sublicense, to use Medarex Developments with respect to the Celldex product that was the 

3

 

subject
of the Clinical/Regulatory Services being performed when the applicable Medarex Development was conceived or reduced to practice. 

2.     SERVICE CHARGE; INVOICING

        2.1    Service Charge.    Unless otherwise agreed in a Service Provision Form, Medarex shall charge Celldex for any
Services provided pursuant to Section 1.1 or Section 1.2 on an hourly basis at a rate that, on a Service-by-Service basis, equals the actual hourly employee
compensation rate for the Medarex employee performing the relevant Service (including a reasonable allocation for payroll taxes, health insurance and other standard fringe benefits), plus a ten
percent (10%) surcharge. Outsourced Services pursuant to Section 1.3 shall be provided and charged through to Celldex at Medarex's actual cost therefor (on a pro-rata basis if
applicable), without markup, commission or other service charge of any kind, subject to the limitations set forth in Section 1.3(c). Any charge for Services or Outsourced Services pursuant to
this Section 2.1 is referred to in this Agreement as a "Service Charge". Notwithstanding the foregoing, in no event shall Medarex charge Celldex
any Service Charge that exceeds the amount charged by Medarex to any third party for such Service. 

        2.2    Invoicing and Settlement of Costs.    

        (a)   Medarex
shall invoice Celldex for all Service Charges for each calendar quarter within sixty (60) days following the end of such calendar quarter;  provided, that any failure to provide an invoice within
such time period shall not relieve Celldex of its obligation to pay any amount not disputed in
good faith under an invoice received after such date, so long as such invoice is received not later than six (6) months following the provision of the relevant Service. All invoices shall
include a reasonably detailed description of the Services covered by the invoice, including by reference to the appropriate sequentially numbered  Exhibit C. 

        (b)   Medarex
shall be responsible for the payment of all third party providers with whom it has contracted in relation to this Agreement, and for all salaries, benefits,
taxes, fees and other liabilities in connection with Medarex's employees and independent contractors. Copies of all invoices from any such third party providers, redacted by Medarex to remove
information and data unrelated to the Services provided to Celldex, shall be included with the quarterly invoices provided to Celldex pursuant to Section 2.2(a). For clarity, Medarex shall
indemnify, defend and hold harmless Celldex from and against Medarex's failure to make payment to third party providers or Medarex's employees as required by this Section 2.2(b), which
indemnification shall be governed by Section 3.1. 

        (c)   Subject
to Section 2.2(d), Celldex shall pay within thirty (30) days following its receipt of any invoice pursuant to Section 2.2(a), without
setoff, all amounts invoiced during the preceding calendar quarter and not disputed in good faith. If Celldex fails to pay any undisputed amount of any quarterly payment within sixty (60) days
following its receipt of any invoice pursuant to Section 2.2(a), Celldex shall pay, in addition to the amount indicated in such invoice, interest on such amount at the rate of the lesser of one
and one half percent (11/2%) per month, or the maximum permitted under applicable law, during the period such amount remains unpaid. 

        (d)   In
the event of a dispute as to the propriety of any amount invoiced pursuant to Section 2.2(a), Celldex shall pay all undisputed amounts, but shall be entitled
to withhold payment of any amount in dispute. Celldex shall notify Medarex within thirty (30) days from receipt of any invoice as to any disputed amounts. Any notice of dispute by Celldex shall
specify the disputed amount and the reasons each such charge is disputed by Celldex. Medarex shall thereafter make available for review by Celldex records relating to the disputed amount so as to
enable the parties to resolve the dispute. In the event that the resolution of such dispute obligates Celldex to pay all or part of the disputed amount, then Celldex shall make such payment of the
amounts withheld 

4

 

within
seven (7) business days of such resolution. The parties shall use reasonable efforts to resolve any such dispute promptly. 

        2.3    Taxes.    Any sales or use taxes determined to be applicable as a result of Services covered by this Agreement
shall be the responsibility of Celldex. All other taxes shall be the responsibility of Medarex. Any taxes for which Celldex is ultimately responsible pursuant to this Section 2.3 but which are
required to be withheld or remitted by Medarex shall be specifically set forth in any applicable invoice, and
Medarex shall deliver with such invoice appropriate documentation regarding the amount and payment to the relevant authority of any such tax. 

        2.4    Audit.    At anytime either during the Services period or for twelve (12) months after completion of
Services, Celldex shall have the right to audit Medarex's books and records to confirm accuracy of all invoices provided hereunder, at reasonable times and places, at Celldex's sole expense, through a
third party selected by Celldex, which third party shall be reasonably acceptable to Medarex and subject to obligations of confidentiality and non-use at least as stringent as those that
apply to Celldex in this Agreement; provided, that Celldex shall not have the right to conduct more than one such audit in any twelve (12)-month period
nor to audit any particular calendar quarter more than one time; and provided further, that in the event such audit reveals that Medarex has overcharged
Celldex for any Services by five percent (5%) or more, Medarex shall refund such overcharges to Celldex within seven (7) business days and shall bear all out-of-pocket
costs and expenses of Celldex incurred in connection with conducting such audit. Unless otherwise agreed to by the parties in writing, Medarex shall retain its books and records relating to the
accounting for the Services provided under any executed Service Provision Form for a period of at least three (3) years following the completion of such Service Provision Form. 

3.     INDEMNIFICATION; LIMITATION OF LIABILITY; REPRESENTATIONS  

        3.1    Indemnification by Medarex.    Medarex shall indemnify, defend and hold harmless Celldex and its affiliates,
and their respective directors, officers, employees and agents, from and against any and all losses, damages, liabilities, reasonable attorney fees, court costs, and expenses (collectively,
"Losses") resulting or arising from any third party claims, actions, proceedings, investigations or litigation (including personal injury or wrongful
death) ("Third Party Claims") relating to or arising from or in connection with this Agreement or any Services, to the extent such Losses resulted from
the gross negligence or intentional or willful misconduct of or by Medarex or its affiliates (other than Celldex), or their respective agents, employees, representatives or affiliates, including any
third party providers pursuant to Section 1.3. 

        3.2    Indemnification by Celldex.    Celldex shall indemnify, defend and hold harmless Medarex and its affiliates,
and their respective directors, officers, employees and agents, from and against any and all Losses resulting or arising from any Third Party Claims relating to or arising from or in connection with
this Agreement or any Services, except, when and only to the extent that (x) Medarex is obligated to indemnify Celldex pursuant to Section 3.1 or (y) such Losses result from the
negligence of or by Medarex or its affiliates (other than Celldex), or their respective agents, employees, representatives or affiliates, including any third party providers pursuant to
Section 1.3 ("Medarex Negligence"). Celldex agrees to reimburse Medarex for the cost of any additional insurance premiums paid by Medarex to
third party insurance providers to obtain insurance coverage with respect to actual or potential Medarex Negligence. 

        3.3    Limitation of Liability.    NOTWITHSTANDING ANYTHING TO THE CONTRARY ANYWHERE IN THIS AGREEMENT, MEDAREX'S
MAXIMUM AGGREGATE LIABILITY UNDER ALL PROVISIONS OF THIS AGREEMENT AND IN ANY WAY ARISING FROM OR IN CONNECTION WITH THE SERVICES AND THIS AGREEMENT SHALL BE LIMITED TO THE AMOUNT PAID BY CELLDEX TO
MEDAREX WITH RESPECT TO THE SERVICE AREA 

5

 

(AS
SET FORTH ON EXHIBIT A) RELEVANT TO THE SERVICE THAT IS THE SUBJECT OF SUCH LIABILITY. 

        3.4    Representations.    

        (a)   Each
of the parties hereto represents and warrants to the other party that (i) it has the corporate power and authority to execute, deliver and perform this
Agreement, (ii) the execution, delivery and performance of this Agreement by it has been duly authorized by all necessary corporate action, (iii) it has duly and validly executed and
delivered this Agreement, and (iv) this Agreement is a legal, valid and binding obligation enforceable against it in accordance with its terms, except as such enforceability may be limited by
bankruptcy, insolvency, moratorium or other similar laws affecting or relating to creditors' rights generally, and subject to general principles of equity. 

        (b)   In
addition, Medarex represents and warrants to Celldex that (i) all its employees, independent contractors and third party providers that are providing Services
to Celldex hereunder have (or will have, prior to providing such Services) executed appropriate intellectual property assignment and confidentiality agreements requiring, in respect of assignment,
obligations sufficient for Medarex to perform its obligations under this Agreement, and, in respect of confidentiality, obligations at least as strict as those set forth in Section 5.1 and
which protect the Confidential Information of Celldex, (ii) it, or its third party providers, has the capability and capacity to perform the agreed-to Services set forth on executed
Service Provision Forms and to otherwise carryout Medarex's obligations under this Agreement, (iii) it will have requisite licenses, permits and approvals necessary to provide the
agreed-to Services set forth on executed Service Provision Forms, and (iv) it will not enter into after the Effective Date any agreements or commitments that could reasonably be
expected to impair or prevent it from carrying out all of its obligations hereunder. 

4.     TERM AND TERMINATION

        4.1    Term; Renewal.    The term of this Agreement shall commence on the Effective Date and shall continue for a
period concluding upon the two (2) year anniversary of the Effective Date; provided, that (a) upon
the mutual written agreement of the parties, the term of the Agreement may be extended for an additional six-month period and (b) notwithstanding the foregoing, unless otherwise
specifically agreed in writing by the parties, this Agreement shall continue and not expire as to any given Service until such Service is completed in accordance with the terms of the relevant
executed Service Provision Form (e.g., provision of a three-year service shall not expire until the completion of such ongoing service). 

        4.2    Termination by Celldex.    This Agreement may be terminated, in whole or on a
Service-by-Service basis, for any reason by Celldex at any time during the term of the Agreement on thirty (30) days' prior written notice to Medarex;  provided, however, that Celldex may not,
pursuant to this Section 4.2, terminate this Agreement or a Service that is subject to a Service
Provision Form then in effect without the prior written consent of Medarex, such consent not to be unreasonably withheld. Any termination of one or more of the Services will not affect the obligations
of Medarex under this Agreement with respect to any other Services. 

        4.3    Termination for Breach.    Either party may terminate this Agreement for material breach of the other party by
giving written notice to the other party and specifying the nature of the alleged breach. If the other party has not cured or commenced efforts to substantially cure such breach within thirty
(30) days following receipt of the notice of breach, then the non-breaching party shall have the right to terminate this Agreement immediately upon written notice to the breaching
party. 

6

 

        4.4    Termination for Bankruptcy.    In the event either party becomes insolvent, makes an assignment for the benefit
of creditors, files a petition for bankruptcy, is the subject of a petition for bankruptcy which is not dismissed within ninety (90) days from the filing thereof, becomes the subject of any
receivership or admits in writing its inability to pay its debt generally as they become due, this Agreement may be terminated by the solvent party, and the solvent party shall be entitled to recover
any payments which could be recovered from the insolvent party in the event of default. 

        4.5    Effect of Termination or Expiration.    Upon termination of any Service (or this Agreement) pursuant to this
Article 4 or Section 5.2, Medarex will have no further obligation to provide the terminated Service (or, in the case of termination or expiration of the Agreement, unless the parties
agree otherwise in writing, any Service), and Celldex shall have no obligation to pay any Service Charges or other fees. Notwithstanding such termination or expiration, (a) except with respect
to a termination by Celldex pursuant to Section 4.3, Celldex shall remain liable to Medarex for Service Charges and amounts owed and payable in respect of Services provided prior to the
effective date of such termination or expiration, (b) Medarex shall remain liable to Celldex in respect of the level of Services provided, as such level is described in the first sentence of
Section 1.4, prior to the effective date of such termination or expiration, (c) each party shall retain all claims, causes of action, defenses, and other rights that it may have at law
or in equity accruing prior to the effective date of such termination or expiration, and (d) the provisions of Sections 1.3(c), 1.3(d), 1.5, 1.6, 1.7, 2.2, 2.3, 2.4, this
Section 4.5, Article 3 and Article 5 shall survive any such termination or expiration. 

5.     MISCELLANEOUS

        5.1    Confidentiality.    

        (a)   Subject
to the exceptions set forth in Section 5.1(b), below, all information and materials that either party receives from the other party pursuant to this
Agreement shall be "Confidential Information" of the disclosing party. 

        (b)   "Confidential Information" shall not be deemed to include information which the receiving party can demonstrate by
competent written proof: (i) is now, or hereafter becomes, through no act or failure to act on the part of the receiving party, in the public domain, (ii) is known by the receiving party
at the time of receiving such information, as evidenced by its prior written records, (iii) is independently developed by or for the receiving party by employees or contractors who did not have
access to the disclosing party's Confidential Information, or (iv) is hereafter furnished to the receiving party by a third party, as a matter of right and without restriction on disclosure.
Notwithstanding the foregoing, Confidential Information assigned to Celldex pursuant to that certain Assignment and License Agreement between the parties executed concurrently herewith shall be deemed
Confidential Information of Celldex hereunder and shall not be permitted to be disclosed by Medarex pursuant to this Section 5.1(b). 

        (c)   Except
as provided hereafter, the receiving party shall maintain all Confidential Information in trust and confidence and shall not use, publish, disseminate or
otherwise disclose any Confidential Information of the disclosing party to any third party without the written consent of the disclosing party. The receiving party may only disclose and disseminate
Confidential Information to those employees or agents of the receiving party with a need to know, and only after such employees or agents have been advised of the confidential nature of such
information and are bound by an obligation of confidentiality to the receiving party under terms substantially similar to the terms of this Agreement. Further, the receiving party shall not use any
Confidential Information of the disclosing party except as necessary for the receiving party to fulfill its obligations under this Agreement. 

        (d)   Notwithstanding
any other provision of this Agreement, disclosure of Confidential Information shall not be prohibited if such disclosure (i) is in response to a
valid order of a court 

7

 

or
other governmental body of the United States or any political subdivision thereof or as required by any stock exchange or similar self-regulatory body;  provided, that the responding party shall first
have given reasonable notice to the other party in order to allow either party hereto to seek a
protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or permission to redact such information from any required
filing, or (ii) is otherwise required by law. 

        (e)   Upon
the disclosing party's request, the receiving party shall return to the disclosing party any or all written, printed, visual, or digital media, documents, tapes,
and other materials or substances containing the disclosing party's Confidential Information, including all copies and excerpts thereof then in the receiving party's possession or control; provided,
however, that the receiving party may keep one copy of such Confidential Information for legal archival purposes only. The return of the disclosing party's Confidential Information shall not relieve
the receiving party of its obligations of confidentiality pursuant to this Section 5.1. 

        (f)    If
either party becomes aware of or has knowledge of any unauthorized use or disclosure of the other party's Confidential Information, it shall promptly notify the
disclosing party of such unauthorized use or disclosure. For clarity, such notification shall not relieve a receiving party of any liability in connection with a breach by it of any of the other
provisions of this Section 5.1. 

        (g)   Each
party recognizes the material nature of the provisions of this Section 5.1 and acknowledges that unauthorized disclosure may cause the disclosing party
irreparable harm, and agrees that any breach or threatened breach of this provision by a receiving party shall entitle the disclosing party to seek injunctive relief, in addition to any other legal or
equitable remedies available to it, in any court of competent jurisdiction. 

        5.2    Force Majeure and Delays.    In the event either party shall be delayed or hindered or prevented from the
performance of any act or Service required hereunder by reasons of strike, lockouts, labor troubles, failure of power, restrictive government or judicial orders or decrees, riots, insurrection, war,
acts of God, inclement weather or other similar reason or cause beyond that party's reasonable control, then performance of such act or Service shall be excused for the period of such delay;  provided,
the party provides notice of the existence of and reason for such nonperformance or delay in specific detail. Medarex will use its reasonable
efforts to restore any affected Service. Notwithstanding the foregoing, in the event that Medarex is unable to restore any such affected Service within thirty (30) days, Celldex shall be
entitled to terminate such affected Service immediately upon written notice to Medarex, without further liability or penalty, but subject to Section 4.5. 

        5.3    Notices.    Any notice required or permitted to be given hereunder by either party shall be in writing and
shall be deemed given on the date received if delivered personally, by facsimile with confirmation of receipt, or by reputable overnight delivery service, or three (3) days after the date
postmarked if sent by registered or certified mail, return receipt requested, postage prepaid, to the following addresses: 

 If to Medarex:  

Medarex, Inc.

707 State Road

Princeton, NJ 08540

Attn: President

Facsimile: (609) 430-2850 

8

 

With
a copy to: 

Medarex, Inc.

707 State Road

Princeton, NJ 08540

Attn: General Counsel

Facsimile: (609) 430-4215 

and
to 

Medarex, Inc.

707 State Road

Princeton, NJ 08540

Attn: Contracts Administrator

Facsimile: (609) 430-4215 

 If to Celldex:  

Celldex
Therapeutics, Inc.

519 Route 173W

Bloomsbury, New Jersey 08804

Attn: Chief Executive Officer

Facsimile: (908) 713-6002 

With
a copy to: 

Morgan,
Lewis & Bockius LLP

502 Carnegie Center

Princeton, New Jersey 08540

Attention: Randall B. Sunberg, Esq.

Facsimile: (877) 432-9652 

        5.4    Independent Contractor.    For purposes of this Agreement, the parties hereto are deemed independent
contractors and nothing contained in this Agreement shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venture partners. Neither party
shall have the power or right to bind or obligate the other party, nor shall either party hold itself out as having such authority. 

        5.5    No License.    Both parties agree not to use any of other party's trademarks or trade names without the prior
express written consent of the other party. Except as expressly set forth herein, nothing in this Agreement shall be construed to create in or grant or provide to a party any license, right, title,
interest, or ownership in or to any of the other party's intellectual property or other proprietary rights of the other party. 

        5.6    Assignment.    This Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and permitted assigns. Neither party may assign any of its rights or obligations under this Agreement to any party without the express written consent of the other party;  provided,
that either party may assign this Agreement without the consent of the other party to an affiliate or to a third party who acquires all or
substantially all of the business of the assigning party by merger, acquisition or transfer of assets. 

        5.7    Choice of Law; Jurisdiction and Venue.    This Agreement shall be construed, governed, interpreted, and applied
in accordance with the laws of the State of New Jersey exclusive of its conflicts of laws provisions. Any claim or controversy arising out of or related to this Agreement or any breach hereof shall be
submitted to a court of applicable jurisdiction in the State of New Jersey, and each party hereby consents to the jurisdiction and venue of such court. 

9

 

        5.8    Waiver.    The failure to enforce any right or provision herein shall not constitute a waiver of that right or
provision. No failure or delay by a party in exercising any right, power or privilege hereunder shall operate as a waiver hereof, nor shall any single or partial exercise thereof preclude any other or
further exercise thereof. 

        5.9    Severability.    If any provisions herein are found to be unenforceable, it is the intent of the parties that
such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law. The invalidity or unenforceability of any provision of
this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, which shall remain in full force and effect. 

        5.10    Entire Agreement and Modification.    This Agreement and the Exhibits (including any executed Service
Provision Forms) attached hereto contain the entire understanding of the parties with respect to the subject matter herein and supersede all previous agreements (oral and written), negotiations and
discussions. In the event of any conflict between the terms and provisions of this Agreement and the terms of any executed Service Provision Forms, the terms of this Agreement shall govern unless the
executed Service Provision Form expressly indicates that it shall govern by use of the phrase "Notwithstanding Section(s) of the Master Services Agreement, the following terms and provisions of this
Service Provision Form shall govern in the event of any conflict between the terms of this Service Provision Form and the terms of Section(s) of the Master Services Agreement". The parties may modify
any of the provisions hereof only by an instrument in writing duly executed by the parties. For avoidance of doubt, the terms of any subsequent pre-printed purchase order shall not vary,
add to or supersede this Agreement. 

        5.11    Headings; Construction.    The headings in this Agreement are intended solely for convenience or reference and
shall be given no effect in the construction or interpretation of this Agreement. Any use
of the word "including" herein shall be deemed followed by the words "but not limited to" or similar words. 

        5.12    Counterparts.    This Agreement may be executed in counterparts, each of which shall be deemed an original and
both of which together shall constitute one and the same instrument. 

[SIGNATURE PAGE FOLLOWS]

10

 

        IN
WITNESS WHEREOF, the parties hereto have caused this Master Services Agreement to be executed by their duly authorized representatives as of the Effective Date. 

	 	 	MEDAREX, INC.
	

 	
 	

By:	
 	

/s/  W. BRADFORD MIDDLEKAUFF      
 Name:  W. Bradford Middlekauff

Title:    Senior Vice President and General Counsel
	

 	
 	
CELLDEX THERAPEUTICS, INC.
	

 	
 	

By:	
 	

/s/  ANTHONY S. MARUCCI      
 Name:  Anthony S. Marucci

Title:    Vice President and Chief Financial Officer

11

CONFIDENTIAL  

EXHIBIT A  

POTENTIAL SERVICES AFTER EFFECTIVE DATE*  

	Service Area
 
	 	Description

	Human Resources	 	General human resources services. Assist Celldex in setting up and managing Celldex benefit plans.
	

Finance	
 	

General finance services.
	

Information Services	
 	

Assist Celldex in setting up an information technology network. Information technology support services.
	

Treasury	
 	

Advice and assistance on treasury-related matters (leasing, letters of credit, investments, pensions, bank relationships, etc.). Assist in establishing a cash management structure and systems.
	

Insurance	
 	

Management and allocation of corporate insurance to Celldex, including but not limited to excess liability, general liability, workers' compensation, fire and vehicle premiums.
	

Clinical/Regulatory	
 	

Clinical and regulatory support services. Assist Celldex in identifying clinical sites for future clinical trials. Advise Celldex on regulatory issues with respect to product development.
	

Additional/Miscellaneous	
 	

Includes support to Celldex for activities such as facilities management, construction, etc.

*In
accordance with Section 1.1(b), all Services to be described in detail and subject to the terms of a Service Provision Form to be attached on  Exhibit C. 

EXHIBIT B  

 TEMPLATE OF SERVICES PROVISION FORM  

	•
	Duration:  From
                        ,
200     to                         , 200    .

	•
	Service to be provided and described on this Services Provision Form (one Service per
form):  

	Human Resources	 	            
	

Finance	
 	

            
	

Information Services	
 	

            
	

Treasury	
 	

            
	

Insurance	
 	

            
	

Clinical/Regulatory	
 	

            
	

Additional/Miscellaneous	
 	

            

	•
	Detailed Description of Service to be provided per this Service Provision Form; identify any
Deliverables  (attach additional sheet(s) as necessary): 

	

	

	

	

	

	 	 •	 	Estimated Number of Hours:	 	            	 	 
	 	
 •	
 	

Estimated Average Service Charge per Hour:	
 	

            	
 	

(Attach additional information
	 	 	as necessary to account for base hourly, benefits allocations, and by-employee variations.)
	 	
 •	
 	
Additional Comments:	
 	

 	
 	

 

	

	

	

Agreed:  

	
	 	

	Celldex Therapeutics, Inc.	 	Medarex, Inc.*

        *
Must be signed by a Senior Vice President of Medarex, Inc. 

EXHIBIT C  

 SERVICE PROVISION FORMS  

        [TO BE ATTACHED BY THE PARTIES AS REQUIRED.]  

QuickLinks

MASTER SERVICES AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.5  

 
 

CONFIDENTIALITY AGREEMENT    
    
    BY AND BETWEEN    
    
    MEDAREX, INC.    
    
    AND    
    
    CELLDEX THERAPEUTICS, INC.    
    
    DATED AS OF APRIL 6, 2004
 
    

CONFIDENTIALITY AGREEMENT  

        This CONFIDENTIALITY AGREEMENT is made and entered into as of April 6, 2004, by and between Medarex, Inc., a New Jersey corporation ("Medarex"), and
Celldex Therapeutics, Inc., a Delaware corporation and a wholly owned subsidiary of Medarex ("Celldex"). 

RECITALS  

        WHEREAS, the Board of Directors of Medarex has determined that it would be in the best interests of Medarex and
its stockholders to separate certain assets and businesses from Medarex; 

        WHEREAS, Medarex has caused Celldex to be incorporated in order to effect such separation; 

        WHEREAS, pursuant to resolutions of its Board of Directors adopted on March 5, 2004, Medarex has contributed certain assets to
Celldex pursuant to that certain Assignment and License Agreement between Medarex and Celldex, dated March 29, 2004; 

        WHEREAS, Celldex intends to file the IPO Registration Statement (as herein defined) with the Securities and Exchange Commission; and 

        WHEREAS, Medarex and Celldex desire to enter into this Agreement concerning the obligations of the parties with respect to confidential or
proprietary information, intellectual property, and other matters that are set forth below. 

        NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements herein contained, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows: 

DEFINITIONS  

        For all purposes of this Agreement, and except as otherwise expressly provided, capitalized terms used herein shall have the following meanings: 

        "AFFILIATE"
means a Celldex Affiliate or a Medarex Affiliate, as the case may be. 

        "BUSINESS
DAY" means any day other than a Saturday, a Sunday, or a day on which banking institutions located in the States of New Jersey or Delaware are obligated by law or executive
order to close. 

        "CELLDEX
AFFILIATE" means a Person that, directly or indirectly, through one or more intermediaries, Controls, is Controlled by, or is under common Control with Celldex (other than
Medarex and any Medarex Affiliate). 

        "CELLDEX
BUSINESS" means the business conducted by Celldex and/or any Celldex Affiliate at any time and from time to time. 

        "CELLDEX
CONFIDENTIAL INFORMATION" means confidential or proprietary information relating to the Celldex Business, including, but not limited to, any unpublished Technology, unpublished
patent applications, and other confidential and proprietary technical and business information relating to the Celldex Business. 

        "CELLDEX"
has the meaning ascribed in the preamble hereto. 

        "CONFIDENTIAL
INFORMATION" means Celldex Confidential Information or Medarex Confidential Information, as the case may be. 

        "CONTROL"
means the possession, direct or indirect, of the power to direct or cause the direction of the management of the policies of a Person, whether through the ownership of voting
securities, by contract or otherwise. 

        "CONTROLLED"
has the meaning correlative to the definition of "CONTROL." 

 

        "COPYRIGHTS"
means all registered and unregistered copyrights and applications therefore. 

        "GOVERNMENTAL
BODY" shall mean any nation, state, province, county, city, town, village, district, or other jurisdiction of any nature; federal, state, provincial, local, municipal,
foreign, or other government; governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal);
multi-national organization or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature. 

        "IPO
REGISTRATION STATEMENT" means the Registration Statement on Form S-1 of Celldex to be filed with the SEC, as supplemented and amended from time to time. 

        "MEDAREX
AFFILIATE" means a Person that, directly or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with Medarex (other than
Celldex and any Celldex Affiliate). 

        "MEDAREX
BUSINESSES" means the businesses conducted by Medarex and/or any Medarex Affiliate at any time, but excluding the Celldex Business. 

        "MEDAREX
CONFIDENTIAL INFORMATION" means confidential or proprietary information relating to the Medarex Businesses, including, but not limited to, any unpublished Technology,
unpublished patent applications, and other confidential or proprietary technical and business information relating to the Medarex Businesses. 

        "MEDAREX"
has the meaning ascribed in the preamble hereto. 

        "PATENTS"
means all United States and foreign patents and patent applications, including any continuations, continuations-in-part, divisions, provisionals,
substitutions or the like, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal, extension or the like (including any supplementary protection
certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, including, as applicable, portions thereof or individual claims
therein. 

        "PERSON"
means an individual, partnership, limited liability company, joint venture, corporation, trust, unincorporated association, any other entity, or any government or any department
or agency or other unit thereof. 

        "PROCEEDING"
shall mean any claim, action, arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal, administrative, investigative or informal) asserted,
commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Body or arbitrator. 

        "TECHNOLOGY"
means all technology and know-how, including without limitation, technical information, trade secrets and knowledge, design rights (other than statutory
registrations), whether included in or derived from specifications, manuals, notebooks, reports, documents, blue prints, inventions, drawings, formulae, procedures, processes, devices, software and
source code and documentation therefor, flow charts, recording media, and other intangible, tangible and electronic embodiments of information. 

1.    CONFIDENTIALITY    

        1.1   Medarex
agrees to keep confidential and not disclose, and shall cause each Medarex Affiliate to keep confidential and not disclose, to any third party and not to use for
any purpose not authorized by Celldex, in whole or in part, any Celldex Confidential Information. 

        1.2   Celldex
agrees to keep confidential and not disclose, and to cause each Celldex Affiliate to keep confidential and not disclose, to any third party and not to use for
any purpose not authorized by Medarex, in whole or in part, any Medarex Confidential Information. 

2

 

        1.3   For
purposes of this Agreement, Medarex Confidential Information and Celldex Confidential Information do not include, and a party and party's Affiliates (a party and
Affiliates of the party being referred to as the "receiving party") will have no obligations under this Agreement, with respect to any information of the other party or any Affiliate of the other
party (the other party and Affiliates of the other party being referred to as the "disclosing party") which: 

          (i)  is
or becomes publicly known through no wrongful act of the receiving party (in which event the receiving party's obligations under this Agreement in respect thereto
shall terminate on the date such information enters the public domain); or 

         (ii)  is
or was rightfully received by the receiving party from a third party without violation of any obligations of confidentiality and/or use restrictions owed by the
third party to the disclosing party or any other party; or 

        (iii)  is
independently developed by employees or consultants of the receiving party without use of or reference to the disclosing party's proprietary information; or 

        (iv)  is
approved for release by the prior written authorization of the disclosing party. 

        In
addition, if the receiving party is requested or required (by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demand, similar
process or otherwise) to disclose any Confidential Information of the disclosing party, such receiving party will provide prompt notice to the disclosing party on such request(s) so that such
disclosing party may seek any appropriate protective order and/or waive compliance with the provisions of this Agreement. Failing the entry of a protective order or the receipt of a waiver hereunder,
if the receiving party is in the opinion of its attorneys legally required to disclose any of the disclosing party's Confidential Information under pain of liability for contempt or other material
censure or material penalty, the receiving party may disclose such Confidential Information without liability hereunder upon notice to the disclosing party. 

2.    COOPERATION    

        2.1   The
parties will take all actions as may be reasonably necessary or appropriate to conform to the purpose and spirit of this Agreement, including, without limitation,
cooperating with the other party in connection with the maintenance, enforcement and protection of the Copyrights, Patents and Technology, and executing any and all documents or instruments, or
obtaining any consents, in order to assign, transfer, perfect, record, maintain, enforce or otherwise carry out the intent of the terms of this Agreement. 

        2.2   Each
party will take all actions as may be reasonably necessary or appropriate to assure the confidentiality and non-use obligations and other applicable
obligations of a party pursuant to this Agreement are met by its legal representatives, members of supervisory bodies, management, employees or other agents. 

3.    MISCELLANEOUS    

        3.1    AUTHORITY.    Each of the parties hereto represents and warrants to the other that (a) it has the
corporate power and authority to execute, deliver and perform this Agreement, (b) the execution, delivery and performance of this Agreement by it has been duly authorized by all necessary
corporate action, (c) it has duly and validly executed and delivered this Agreement, and (d) this Agreement is a legal, valid and binding obligation, enforceable against it in accordance
with its terms subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors' rights generally and general equity principles. The representations
and warranties contained in this Section 3.1 shall survive the execution and delivery hereof until the expiration of all applicable statutes of limitations. 

3

 

        3.2    COMPLETE AGREEMENT.    This Agreement constitutes the entire agreement between the parties hereto with respect
to the subject matter hereof and shall supersede all prior agreements and understandings, whether written or oral, between the parties with respect to such subject matter. 

        3.3    GOVERNING LAW.    This Agreement shall be governed by and construed in accordance with the laws of the State of
New Jersey (without giving effect to the conflict of laws principles thereof) as to all matters, including without limitation, matters of validity, construction, effect, performance and remedies. 

        3.4    NOTICES.    All notices and other communications hereunder shall be in writing and shall be delivered in
person, by telecopy, by express or overnight mail delivered by a nationally recognized air courier (delivery charges prepaid), or by registered or certified mail (postage prepaid, return receipt
requested) to the respective parties as follows: 

	(a)
	If
to Medarex, to: 

Medarex, Inc.

707 State Road

Princeton, NJ 08540

ATTN: President 

With
a copy to: 

Medarex, Inc.

707 State Road

Princeton, NJ 08540

ATTN: General Counsel 

	(b)
	If
to Celldex, to: 

Celldex
Therapeutics, Inc.

519 Route 173 West

Bloomsbury, NJ 08804

Attn: Vice President and Chief Financial Officer 

With
a copy to: 

Morgan,
Lewis & Bockius LLP

502 Carnegie Center

Princeton, New Jersey 08540

ATTN: Randall B. Sunberg, Esq. 

or
to such other address as the party to whom notice is given may have previously furnished to the others in writing in the manner set forth above. Any notice or communication delivered in person
shall be deemed effective on delivery or when delivery is refused. Any notice or communication sent by telecopy or by air courier shall be deemed effective on the first Business Day at the place at
which such notice or communication is received following the day on which such notice or communication was sent. 

        3.5    AMENDMENT AND MODIFICATION.    This Agreement may not be amended or modified in any respect except by a written
agreement signed by both of the parties hereto. 

        3.6    BINDING EFFECT; ASSIGNMENT.    This Agreement and all of the provisions hereof shall be binding upon the
parties hereto and inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assigned by either party hereto without the prior written consent of the other party provided, however, that either party may assign this Agreement, without the other party's consent 

4

 

(a) to
its Affiliate, or (b) to an entity that acquires all or substantially all of the business or assets of the assigning party, whether by merger, reorganization, acquisition, sale or
otherwise. 

        3.7    THIRD PARTY BENEFICIARIES.    Nothing in this Agreement, express or implied, is intended to or shall confer
upon any Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, and no Person (other than as provided in the previous sentence) shall be
deemed a third party beneficiary under or by reason of this Agreement. 

        3.8    COUNTERPARTS.    This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. The Agreement may be executed by facsimile signature. 

        3.9    WAIVER.    The observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively) by the party entitled to enforce such term, but such waiver shall be effective only if it is in writing signed by the party against which such
waiver is to be asserted. Unless otherwise expressly provided in this Agreement, no delay or omission on the part of any party in exercising any right or privilege under this Agreement shall operate
as a waiver thereof, nor shall any waiver on the part of any party of any right or privilege under this Agreement operate as a waiver of any other right or privilege under this Agreement nor shall any
single or partial exercise of any right or privilege preclude any other or further exercise thereof or the exercise of any other right or privilege under this Agreement. No failure by either party to
take any action or assert any right or privilege hereunder shall be deemed to be a waiver of such right or privilege in the event of the continuation or repetition of the circumstances giving rise to
such right unless expressly waived in writing by the party against whom the existence of such waiver is asserted. 

        3.10    SEVERABILITY.    Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof. Any such prohibition or unenforceability in
any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 

        3.11    REMEDIES.    Each of Medarex and Celldex shall be entitled to seek enforcement of its rights under this
Agreement specifically and recovery of damages and costs (including reasonable attorneys' fees) caused by any breach of any provision of this Agreement and to exercise all other rights existing in its
favor. Each of Medarex and Celldex acknowledges and agrees that under certain circumstances the breach by Medarex or any of its Affiliates or Celldex or any of its Affiliates or a term or provision of
this Agreement will materially and irreparably harm the other party, that money damages will accordingly not be an adequate remedy for such breach and that the non-defaulting party, in its
sole discretion and in addition to its rights under this Agreement and any other remedies it may have at law or in equity, may apply to any court of law or equity of competent jurisdiction (without
posting any bond or deposit) for specific performance and/or other injunctive relief in order to enforce or prevent any breach of the provisions of this Agreement. 

        3.12    PERFORMANCE.    Each of the parties hereto shall use all commercially reasonable efforts to cause to be
performed all actions, agreements and obligations set forth herein to be performed by any Affiliate of such party. 

        3.13    REFERENCES; CONSTRUCTION.    The section and other headings and subheadings contained in this Agreement are
solely for the purpose of reference, are not part of the agreement of the parties hereto, and shall not in any way affect the meaning or interpretation of this Agreement. All references to days or
months shall be deemed references to calendar days or months. Unless the context otherwise requires, any reference to a "Section" shall be deemed to refer to a section of this Agreement. The words
"hereof," "herein" and "hereunder" and words of similar import referring to 

5

 

this
Agreement refer to this Agreement as whole and not to any particular provision of this Agreement. Whenever the words "include," or "including" are used in this Agreement, unless otherwise
specifically provided, they shall be deemed to be followed by the words "without limitation." This Agreement shall be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting or causing the document to be drafted. 

[Signature
page follows.] 

6

 

        IN WITNESS WHEREOF, each of the parties has caused this Confidentiality Agreement to be executed on its behalf by an officer thereunto
duly authorized on the day and year first above written. 

	CELLDEX THERAPEUTICS, INC.	 	MEDAREX, INC.
	 	 	 	 	 	 	 
	By:	 	/s/  ANTHONY S. MARUCCI      
	 	By:	 	/s/  W. BRADFORD MIDDLEKAUFF      

	 	 	 	 	 	 	 
	Name:	 	Anthony S. Marucci	 	Name:	 	W. Bradford Middlekauff
	 	 	 	 	 	 	 
	Title:	 	Vice President & Chief Financial Officer	 	Title:	 	Senior Vice President & General Counsel

7

QuickLinks

CONFIDENTIALITY AGREEMENT BY AND BETWEEN MEDAREX, INC. AND CELLDEX THERAPEUTICS, INC. DATED AS OF APRIL 6, 2004

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]